Medivation Inc  

(Public, NASDAQ:MDVN)   Watch this stock  
Find more results for mdvn
60.02
-0.28 (-0.46%)
Real-time:   2:26PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 59.45 - 61.00
52 week 26.41 - 62.94
Open 60.18
Vol / Avg. 1.05M/2.35M
Mkt cap 9.78B
P/E 41.99
Div/yield     -
EPS 1.43
Shares 164.62M
Beta 0.95
Inst. own 92%
Aug 4, 2016
Q2 2016 Medivation Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 22, 2016
Medivation Inc Annual Shareholders Meeting
Jun 15, 2016
Medivation Inc Annual Shareholders Meeting (Estimated)
Jun 9, 2016
Medivation Inc at Jefferies Healthcare Conference
Jun 7, 2016
Medivation Inc at Goldman Sachs Global Healthcare Conference
May 23, 2016
Medivation Inc at UBS Global Healthcare Conference
May 11, 2016
Medivation Inc at Bank of America Merrill Lynch Health Care Conference
May 5, 2016
Q1 2016 Medivation Inc Earnings Call - Webcast
May 5, 2016
Q1 2016 Medivation Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 2.64% 25.94%
Operating margin 4.43% 41.72%
EBITD margin - 44.70%
Return on average assets 1.40% 20.89%
Return on average equity 2.18% 37.02%
Employees 628 -
CDP Score - -

Address

525 Market St Fl 36
SAN FRANCISCO, CA 94105-2747
United States - Map
+1-415-5433470 (Phone)
+1-415-5433411 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc. (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe and other countries across the world for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company, in collaboration with Astellas, is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. It has developed a small molecule inhibitor of the sterol regulatory element-binding protein, or SREBP, pathway which it refers to as MDV4463.

Officers and directors

Kim D. Blickenstaff Independent Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
David T. Hung M.D. President, Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Jennifer Jarrett Chief Financial Officer
Age: 45
Bio & Compensation  - Reuters
Marion McCourt Chief Operating Officer
Age: 56
Bio & Compensation  - Reuters
Andrew Kenneth William Powell Senior Vice President, General Counsel, Corporate Secretary
Age: 58
Bio & Compensation  - Reuters
Mohammad Hirmand Interim Chief Medical Officer
Age: 46
Bio & Compensation  - Reuters
Michael L. King Ph.D. Director
Age: 63
Bio & Compensation  - Reuters
C. Patrick Machado J.D. Director
Age: 52
Bio & Compensation  - Reuters
Kathryn E. Falberg Independent Director
Age: 55
Bio & Compensation  - Reuters
Dawn Svoronos Independent Director
Age: 62
Bio & Compensation  - Reuters